Author Archives: BPI Staff

Repligen boosting single-use portfolio with Engineered Molding Technology buy

Repligen will add silicone single-use consumables and components for bioprocessing functions through the addition of Engineered Molding Technology (EMT). The size of the deal has not been divulged, but Repligen will expand its single-use filtration and chromatography system component portfolio with custom molded and over-molded connectors and silicone tubing products. “The acquisition of EMT expands our line of single-use ProConne® flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use…

News of note: Sanofi’s €610 million vaccine boost

Sanofi will build a production site and an R&D facility near Lyon in efforts to make homeland France the center of its global vaccine efforts. The plant in Neuville sur Saône, north of Lyon, France, represents an investment of €490 million ($550 million). It will be modular in its design and dedicated to vaccine production and is being set up to respond to future epidemics. The R&D center in Marcy-l’Etoile, west of Lyon, represents €120 million and will look to…

In brief: Single-use manufacturing begins at Meissner’s Irish plant

Meissner says the production of single-use systems has begun from its newly-established site in County Mayo, Ireland. The filtration firm announced in February 2019 plans to establish a production site in Castlebar, Ireland to support demand for its single-use products form the biopharma industry. Sixteen months on and the facility has begun supplying the space after a 10,000 square-foot ISO class 7 cleanroom was completed in mid-April. With the current COVID-19 crisis still ongoing, there was no ribbon-cutting ceremony. “This…

In brief: GSK inks $231m ‘flexible’ deal with Samsung BioLogics

GSK says the eight-year agreement with the Korean CDMO brings additional and flexible capacity to manufacture its innovative biopharmaceutical therapies. UK-headquartered pharma giant GlaxoSmithKline (GSK) has an extensive manufacturing network to support its biologics product portfolio but has turned to contract development and manufacturing organization (CDMO) Samsung BioLogics to secure capacity for future needs. The deal will see Samsung Biologics provide GSK with additional capacity for large-scale biomanufacturing from its site in Incheon, South Korea. The capacity will be flexible…

Viral vector vaccines and a nucleotide: Merck enters the COVID game

A triumvirate of deals, including the acquisition of a firm that uses the measles virus as a carrier for vaccines, sees Merck & Co. jumpstart its COVID-19 efforts. The first of the three announcements – which all came on the same day – will see Merck & Co. acquire vaccine developer Themis. The private Austrian firm is already working with Merck to develop vaccine candidates using its viral vector platform. The technology, developed at the Institut Pasteur and licensed to…

Fujifilm licenses AAV vector tech to speed gene therapy production

CDMO Fujifilm Diosynth Biotechnologies (FDB) says partnering with OXGENE could reduce the lead time of its customers’ gene therapy projects by up to 25%. The technology, licensed from UK-based OXGENE for an undisclosed fee, consists of Helper, Rep/Cap and Gene of Interest plasmids, used in combination with a clonal suspension a HEK293 cell line. The AAV system is expected to reduce the length of the supply chain gene therapy customers, according to contract development and manufacturing organization (CDMO) FDB, with…

In brief: CDMO Cobra collaborates on coronavirus vaccine

Cobra Biologics and the Karolinska Institutet with EU Horizon 2020 emergency funding in hand have teamed to develop a DNA vaccine against COVID-19. Contract development and manufacturing organization (CDMO) Cobra Biologics and Swedish medical university form part of a consortium called OPENCORONA aimed at developing and manufacturing a DNA vaccine against the novel coronavirus (COVID-19) set to be delivered to patient muscle to generate  a viral antigen on which the immune system then reacts. The consortium, which also includes Karolinska…

Eppendorf expands centrifuge business with Koki buy

Eppendorf says the addition of Koki Holdings’ centrifuge business will help provide its biopharma customers a full product portfolio for centrifugation steps in clinical trial, drug discovery and production. The deal – financials of which have not been disclosed – sees German bioprocess vendor Eppendorf expand its business through the addition of Tokyo, Japan-based Koki’s ‘himac’ brand of centrifuge equipment. “A full functioning business organization, including R&D, operations, sales/service and business administration will be carved out of Koki Holdings Co.,”…

Fujifilm breaks ground on $14.5m UK biocampus

Fujifilm Diosynth Biotechnologies says the site in Billingham will support biologic, vaccine and gene therapy development and manufacturing for its customers. Work began on the site in Billingham in the North of England this week, 10 months after the contract development and manufacturing organization (CDMO) first announced plans for the biocampus to support its pharma clients in the development and manufacture of biologics, vaccines and gene therapies. The expansion, set to represent an investment of up to $14.5 million (€13…

Gilead: $4.9bn Forty Seven buy sits in the oncology ‘sweet spot’

The acquisition of monoclonal antibody developer Forty Seven complements Kite’s CAR-T therapy franchise in targeting cancers, says Gilead. Under deal terms announced Monday, Gilead will pay $95.50 (€85.50) for each share of Menlo Park, California-based Forty Seven, totaling $4.9 billion. Forty Seven’s lead CD47-blocking drug, an antibody called magrolimab, is being tested in combination with chemotherapy in separate studies evaluating it as a treatment for two types of blood cancer: a group of disorders called myelodysplastic syndromes (MDS) and acute…